Prevention and early detection of prostate cancer.

[1]  T. Peters,et al.  Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. , 2014, The Lancet. Oncology.

[2]  Hans Garmo,et al.  Radical prostatectomy or watchful waiting in early prostate cancer. , 2014, The New England journal of medicine.

[3]  T. D. de Reijke,et al.  Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. , 2014, European urology.

[4]  H. Ahmed,et al.  Multiparametric Magnetic Resonance Imaging in the Management and Diagnosis of Prostate Cancer: Current Applications and Strategies , 2014, Current Urology Reports.

[5]  H. Grönberg,et al.  A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. , 2014, European urology.

[6]  M. Marberger,et al.  Risk adapted chemoprevention for prostate cancer: an option? , 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[7]  H. Parnes,et al.  Prostate cancer prevention: agent development strategies. , 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[8]  A. Wolk,et al.  Lifestyle and dietary factors in prostate cancer prevention. , 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[9]  R. Eeles,et al.  Germline genetic variants associated with prostate cancer and potential relevance to clinical practice. , 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[10]  G. L. Gabor Miklos,et al.  Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection. , 2013, Journal of the National Cancer Institute.

[11]  Ian M Thompson,et al.  Long-term survival of participants in the prostate cancer prevention trial. , 2013, The New England journal of medicine.

[12]  L. Holmberg,et al.  Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study , 2013, BMJ.

[13]  H. Laydner,et al.  Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis. , 2013, Journal of the American Academy of Dermatology.

[14]  R. Eeles,et al.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Scardino,et al.  Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study , 2013, BMJ : British Medical Journal.

[16]  R. Autorino,et al.  Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy , 2013, The Prostate.

[17]  M. Truong,et al.  Toward the detection of prostate cancer in urine: a critical analysis. , 2013, The Journal of urology.

[18]  Peter Kraft,et al.  Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array , 2013, Nature Genetics.

[19]  M. Kohli,et al.  Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003-2006. , 2013, Mayo Clinic proceedings.

[20]  D. Ankerst,et al.  Prostate cancer incidence and survival in immigrants to Sweden , 2013, World Journal of Urology.

[21]  F. Schifano,et al.  Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies , 2012, PloS one.

[22]  J. Kaldor,et al.  Sun exposure may increase risk of prostate cancer in the high UV environment of New South Wales, Australia: A case–control study , 2012, International journal of cancer.

[23]  R. Reeves,et al.  Trichomonosis, a Common Curable STI, and Prostate Carcinogenesis—A Proposed Molecular Mechanism , 2012, PLoS pathogens.

[24]  A. Wolk,et al.  Dietary cadmium exposure and prostate cancer incidence: a population-based prospective cohort study , 2012, British Journal of Cancer.

[25]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.

[26]  J. Cuzick,et al.  Aspirin and cancer risk: a quantitative review to 2011. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  A. Jemal,et al.  International variation in prostate cancer incidence and mortality rates. , 2012, European urology.

[28]  M. Thun,et al.  The role of aspirin in cancer prevention , 2012, Nature Reviews Clinical Oncology.

[29]  F. Montorsi,et al.  Usefulness of prostate‐specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study , 2012, BJU international.

[30]  M. Lucia,et al.  Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial , 2012, The Lancet.

[31]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[32]  R. Merrill,et al.  Risk‐adjusted incidence rates for prostate cancer in the United States , 2012, The Prostate.

[33]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[34]  C. Lawton,et al.  Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) , 2012 .

[35]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[36]  Hideaki Mizuno,et al.  Molecular classification of prostate cancer using curated expression signatures , 2011, Proceedings of the National Academy of Sciences.

[37]  D. Ilic,et al.  Lycopene for the prevention of prostate cancer. , 2011, The Cochrane database of systematic reviews.

[38]  Jie Ge,et al.  Does physical activity reduce the risk of prostate cancer? A systematic review and meta-analysis. , 2011, European urology.

[39]  A. Partin,et al.  Increased gene copy number of ERG on chromosome 21 but not TMPRSS2–ERG fusion predicts outcome in prostatic adenocarcinomas , 2011, Modern Pathology.

[40]  T. Nawrot,et al.  An Epidemiological Reappraisal of the Familial Aggregation of Prostate Cancer: A Meta-Analysis , 2011, PloS one.

[41]  Jianfeng Xu,et al.  PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients , 2011, Clinical Cancer Research.

[42]  John T. Wei,et al.  A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. , 2011, The Journal of urology.

[43]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[44]  Gerald C. Chu,et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.

[45]  P. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials , 2011, The Lancet.

[46]  R. Eeles,et al.  Hand pattern indicates prostate cancer risk , 2010, British Journal of Cancer.

[47]  Ross J. Harris,et al.  Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis , 2011, Cancer Causes & Control.

[48]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[49]  P. Scardino,et al.  Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study , 2010, BMJ : British Medical Journal.

[50]  B. Ma,et al.  Efficacy of Antioxidant Vitamins and Selenium Supplement in Prostate Cancer Prevention: A Meta-Analysis of Randomized Controlled Trials , 2010, Nutrition and cancer.

[51]  P. Galan,et al.  Beta‐carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials , 2010, International Journal of Cancer.

[52]  P. Prorok,et al.  Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial , 2010, Clinical trials.

[53]  Kim Pettersson,et al.  Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  E. Steyerberg,et al.  The effect of study arm on prostate cancer treatment in the large screening trial ERSPC , 2010, International journal of cancer.

[55]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[56]  B. Kupelnick,et al.  Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. , 2010, American journal of public health.

[57]  W. Gerald,et al.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.

[58]  P. Lange.  Re: Effect of Dutasteride on the Risk of Prostate Cancer Andriole GL, Bostwick DG, Brawley OW, et al. REDUCE Study Group , 2010 .

[59]  J. Kliment.  Re: Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. , 2009, European urology.

[60]  J. Cuzick,et al.  p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer , 2009, BJU international.

[61]  E. Giovannucci,et al.  Smoking and aggressive prostate cancer: a review of the epidemiologic evidence , 2009, Cancer Causes & Control.

[62]  J. Cuzick,et al.  Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study , 2009, British Journal of Cancer.

[63]  W. Goggins,et al.  Cancer among Asian Indians/Pakistanis living in the United States: low incidence and generally above average survival , 2009, Cancer Causes & Control.

[64]  C. Magi-Galluzzi,et al.  Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. , 2008, Urology.

[65]  François G. Meyer,et al.  Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies , 2008, Annals of Internal Medicine.

[66]  Ross J. Harris,et al.  Height and Prostate Cancer Risk: A Large Nested Case-Control Study (ProtecT) and Meta-analysis , 2008, Cancer Epidemiology Biomarkers & Prevention.

[67]  S. Bonovas,et al.  Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies , 2008, International journal of cancer.

[68]  M. Gleave,et al.  Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer , 2008, BMC Cancer.

[69]  I. Thompson,et al.  Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach , 2008, Cancer Prevention Research.

[70]  E. Platz,et al.  Inflammation and prostate cancer: A focus on infections , 2008, Current urology reports.

[71]  R. Eeles,et al.  Diagnostic radiation procedures and risk of prostate cancer , 2008, British Journal of Cancer.

[72]  A. Roddam,et al.  Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. , 2008, Journal of the National Cancer Institute.

[73]  T. Ahlering,et al.  The Effect of Difluoromethylornithine on Decreasing Prostate Size and Polyamines in Men: Results of a Year-Long Phase IIb Randomized Placebo-Controlled Chemoprevention Trial , 2008, Cancer Epidemiology Biomarkers & Prevention.

[74]  R. Henrique,et al.  Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. , 2007, European urology.

[75]  J. Gohagan,et al.  Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian cancer screening trial , 2007, BJU international.

[76]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[77]  I. Thompson,et al.  Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial , 2006, Cancer Epidemiology Biomarkers & Prevention.

[78]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[79]  M. Etminan,et al.  The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[80]  P. Armitage,et al.  The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis , 1954, British Journal of Cancer.

[81]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[82]  J. Hugosson,et al.  Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening. , 2003, European urology.

[83]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[84]  W. Isaacs,et al.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.

[85]  E. Crawford,et al.  Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. , 1998, Urology.

[86]  F. Hamdy,et al.  Screening for Prostate Cancer , 2006 .

[87]  A. Lilienfeld,et al.  Cancer in the United States , 1974 .

[88]  P. Armitage,et al.  A Two-stage Theory of Carcinogenesis in Relation to the Age Distribution of Human Cancer , 1957, British Journal of Cancer.